Skip to main content
Premium Trial:

Request an Annual Quote

Sequenta Secures Rights to iRepertoire IP for Immune Cell Sequencing

NEW YORK (GenomeWeb News) – Sequenta has gained the exclusive rights to iRepertoire's IP related to methods of immune cell sequencing for minimal residual disease testing, the two companies said today.

iRepertoire's IP complements Sequenta's existing MRD patents and strengthens its ability to provide new products and new features, they said. Sequenta in February began offering its ClonoSight test through its CLIA laboratory. The test is based on the South San Francisco, Calif.-based company's LymphoSight technology, which sequences unique DNA signatures present in immune cells, allowing researchers to track malignant sub-populations at levels as low as one cell per million white blood cells.

Last month, Sequenta said it raised $20 million in a Series C financing round.

iRepertoire, headquartered in Huntsville, Ala., markets tools for immune profiling. Through its R10k program it also discovers and develops immune repertoire signatures.

"This deal underscores the value of immune cell profiling and of our platform and will enable us to move our business forward in other areas," iRepertoire CEO Jian Han said in a statement.

Financial and other terms of the deal were not disclosed.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.